Alvotech joins forces with Polifarma for proposed biosimilar Eylea
Alvotech, a global biotech company specializing in developing and manufacturing biosimilar medicines for patients worldwide, has entered into an exclusive agreement with Polifarma. The deal entails the commercialization in Turkey of AVT06, a proposed biosimilar to Eylea (aflibercept).
“It is a pleasure to join forces with Polifarma in the commercialization of a potential therapy in eye disease,” said Robert Wessman, chairman and CEO of Alvotech. “We are committed to providing better patient access to affordable biologics, and this agreement will allow us to better serve the growing and important Turkish market.”
Read more: Challenges continue, but generics companies see a bright future with biosimilars]
"Polifarma has been contributing to public health and the health sector in the world for 37 years with its motto of 'We stand by life'. This agreement with Alvotech allows us to expand our portfolio and further strengthen our position in the ophthalmology area. We are excited to have the opportunity to commercialize this product in Turkey," said Mehmet Asri, CEO of Polifarma.
[Read more: AAM report: Generics, biosimilars generated $373B savings in 2021]
Alvotech will be responsible for development and manufacture, while Polifarma will handle market registration and commercialization.
AVT06 is a biosimilar candidate currently in clinical development. In July 2022, Alvotech announced the initiation of a patient study to compare AVT06 and Eylea in terms of efficacy, safety and immunogenicity in adult patients with neovascular (wet) age-related macular degeneration.